Drug name - Tasigna

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(6 months from now)

US8415363 NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8163904 NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Aug, 2028

(5 years from now)

US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791

(Pediatric)

NOVARTIS Inhibitors of tyrosine kinases
Jan, 2024

(1 year, 29 days from now)

US8501760 NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jul, 2026

(3 years from now)

US8389537 NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8415363

(Pediatric)

NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(4 years from now)

US8501760

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jan, 2027

(4 years from now)

US8389537

(Pediatric)

NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(4 years from now)

US8293756 NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Sep, 2027

(4 years from now)

US8293756

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Mar, 2028

(5 years from now)

US8163904

(Pediatric)

NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Feb, 2029

(6 years from now)

US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 23, 2028
Pediatric Exclusivity (PED) Sep 22, 2025

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2007

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription
EQ 200MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in